Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ROIV
stocks logo

ROIV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
8.07M
-10.54%
-0.310
-234.85%
8.37M
+10.52%
-0.333
+14.84%
18.53M
+753.87%
-0.390
+18.18%
Estimates Revision
The market is revising Downward the revenue expectations for Roivant Sciences Ltd. (ROIV) for FY2026, with the revenue forecasts being adjusted by -21.11% over the past three months. During the same period, the stock price has changed by 63.93%.
Revenue Estimates for FY2026
Revise Downward
down Image
-21.11%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-13.94%
In Past 3 Month
Stock Price
Go Up
up Image
+63.93%
In Past 3 Month
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 24.50 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 24.50 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.180
sliders
Low
22.00
Averages
24.50
High
28.00
Current: 21.180
sliders
Low
22.00
Averages
24.50
High
28.00
H.C. Wainwright
Douglas Tsao
Buy
maintain
$20 -> $23
2025-11-14
Reason
H.C. Wainwright
Douglas Tsao
Price Target
$20 -> $23
2025-11-14
maintain
Buy
Reason
H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Roivant Sciences to $23 from $20 and keeps a Buy rating on the shares. The company postponed topline data from two Phase 3 trials of batoclimab to 1H26 from 2H25, which management attributed to competitive reasons, the analyst tells investors in a research note.
Guggenheim
Yastin Suneja
Buy
maintain
$21 -> $25
2025-11-14
Reason
Guggenheim
Yastin Suneja
Price Target
$21 -> $25
2025-11-14
maintain
Buy
Reason
Guggenheim analyst Yastin Suneja raised the firm's price target on Roivant Sciences to $25 from $21 and keeps a Buy rating on the shares after updating the firm's model to reflect current spend rates and pipeline updates following the company's Q3 report.
Citi
Samantha Semenkow
Buy
maintain
$25 -> $26
2025-11-10
Reason
Citi
Samantha Semenkow
Price Target
$25 -> $26
2025-11-10
maintain
Buy
Reason
Citi analyst Samantha Semenkow raised the firm's price target on Roivant Sciences to $26 from $25 and keeps a Buy rating on the shares following the fiscal Q2 report. The company will now present data from both batoclimab Phase 3 thyroid eye disease trials in 2026, the analyst tells investors in a research note. Citi sees Roivant's investor day on December 11 laying a catalyst path for the shares in 2026.
Citi
Buy
upgrade
$16 -> $25
2025-10-29
Reason
Citi
Price Target
$16 -> $25
2025-10-29
upgrade
Buy
Reason
Citi raised the firm's price target on Roivant Sciences to $25 from $16 and keeps a Buy rating on the shares. The firm adjusted biotech price targets as part of a Q3 earnings preview.
H.C. Wainwright
Buy
maintain
$18 -> $20
2025-09-18
Reason
H.C. Wainwright
Price Target
$18 -> $20
2025-09-18
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Roivant Sciences to $20 from $18 and keeps a Buy rating on the shares. The firm is "impressed" by the Phase 3 VALOR data of brepocitinib in dermatomyositis. The "fast and durable improvement across broad disease symptoms in brepo-treated patients is particularly significant," the analyst tells investors in a research note. H.C. Wainwright thinks brepocitinib is well positioned to become the first targeted therapy dermatomyositis in 2027.
JPMorgan
NULL -> Overweight
upgrade
$16 -> $20
2025-09-18
Reason
JPMorgan
Price Target
$16 -> $20
2025-09-18
upgrade
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Roivant Sciences to $20 from $16 and keeps an Overweight rating on the shares. The firm says the efficacy and safety from the VALOR study for brepocitinib in dermatomyositis "were as clear as it could be." The efficacy was strong, as brepocitinib's effect on the TIS score fell within JPMorgan's win scenario, the analyst tells investors in a research note. The firm upped its probability of success to 90% for brepocitinib in the U.S. from 40%.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Roivant Sciences Ltd (ROIV.O) is -14.93, compared to its 5-year average forward P/E of -7.40. For a more detailed relative valuation and DCF analysis to assess Roivant Sciences Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.40
Current PE
-14.93
Overvalued PE
-2.82
Undervalued PE
-11.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.74
Undervalued EV/EBITDA
-5.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
87.95
Current PS
0.00
Overvalued PS
196.65
Undervalued PS
-20.76
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 342.9% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 342.9% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ROIV News & Events

Events Timeline

(ET)
2025-11-10
07:04:07
Roivant Sciences anticipates sufficient funds to reach profitability.
select
2025-11-10
07:03:40
Roivant Sciences announces Q2 EPS of 17 cents, falling short of consensus estimate of 30 cents.
select
2025-11-03 (ET)
2025-11-03
08:05:23
Sokolove Named Chief Medical Officer at Vor Bio
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-11NASDAQ.COM
ROIV Surpasses Average Analyst Price Target

  • Current Stock Performance: Roivant Sciences Ltd (ROIV) shares have surpassed the average analyst 12-month target price of $20.86, trading at $21.17/share, prompting potential analyst reactions regarding valuation adjustments.

  • Analyst Target Range: There are 11 analyst targets for ROIV, with estimates ranging from a low of $16.00 to a high of $25.00, indicating a standard deviation of $2.811 among the predictions.

  • Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock's valuation is justified or if it may be time to consider selling some shares.

  • Analyst Rating System: The article references an analyst rating scale from 1 (Strong Buy) to 5 (Strong Sell), providing insight into the overall sentiment towards Roivant Sciences Ltd.

[object Object]
Preview
9.5
11-11Yahoo Finance
Will the Decline in Revenue Growth at Roivant Sciences (ROIV) Impact Its Future Innovation Narrative?

  • Financial Performance: Roivant Sciences reported a quarterly sales of $1.57 million and a net loss of $113.52 million for Q2 2025, indicating a decline in sales and ongoing challenges in revenue growth despite a narrowing net loss compared to the previous year.

  • Investment Outlook: The company's future success hinges on the ability to translate its clinical pipeline, particularly with late-stage programs like brepocitinib, into commercial success, while facing execution risks in clinical trials that could impact investor confidence.

  • Revenue Projections: Roivant is projected to achieve $520.7 million in revenue by 2028, but earnings are expected to decline sharply from $4.6 billion to $83.8 million, raising concerns about the sustainability of its financial health.

  • Market Sentiment: Fair value estimates for Roivant's stock vary significantly, ranging from $6.84 to $20.86 per share, reflecting differing investor perspectives on the company's potential amidst ongoing execution risks in its clinical trials.

[object Object]
Preview
9.5
11-10SeekingAlpha
Roivant Sciences Reports GAAP EPS of -$0.17, Exceeding Estimates by $0.16; Revenue of $1.57M Falls Short by $5.35M

  • Earnings Report: Roivant Sciences (ROIV) reported a Q2 GAAP EPS of -$0.17, exceeding expectations by $0.16.

  • Revenue Performance: The company generated revenue of $1.57 million, which represents a 65% year-over-year decline and fell short of estimates by $5.35 million.

  • Upcoming Presentations: Roivant Sciences is scheduled to present at the Bernstein 2nd Annual Global Healthcare Conference and the Bank of America Global Healthcare Conference in 2025.

  • Investment Activity: The Baron Health Care Fund has made recent investments in Roivant Sciences along with ABBV and UNH, while exiting positions in WAT and COO.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Roivant Sciences Ltd (ROIV) stock price today?

The current price of ROIV is 21.18 USD — it has increased 2.32 % in the last trading day.

arrow icon

What is Roivant Sciences Ltd (ROIV)'s business?

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

arrow icon

What is the price predicton of ROIV Stock?

Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 24.50 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Roivant Sciences Ltd (ROIV)'s revenue for the last quarter?

Roivant Sciences Ltd revenue for the last quarter amounts to 1.57M USD, decreased -64.89 % YoY.

arrow icon

What is Roivant Sciences Ltd (ROIV)'s earnings per share (EPS) for the last quarter?

Roivant Sciences Ltd. EPS for the last quarter amounts to -0.17 USD, decreased -45.16 % YoY.

arrow icon

What changes have occurred in the market's expectations for Roivant Sciences Ltd (ROIV)'s fundamentals?

The market is revising Downward the revenue expectations for Roivant Sciences Ltd. (ROIV) for FY2026, with the revenue forecasts being adjusted by -21.11% over the past three months. During the same period, the stock price has changed by 63.93%.
arrow icon

How many employees does Roivant Sciences Ltd (ROIV). have?

Roivant Sciences Ltd (ROIV) has 750 emplpoyees as of December 05 2025.

arrow icon

What is Roivant Sciences Ltd (ROIV) market cap?

Today ROIV has the market capitalization of 14.73B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free